Patents by Inventor Rohn Millican

Rohn Millican has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glycol Linked Fgf-21 Compounds
    Publication number: 20070265200
    Abstract: The invention provides FGF-21 compounds covalently attached to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active polypeptide with an extended elimination half-life and a slower clearance when compared to that of non-PEGylated polypeptide. These PEGylated FGF-21 compounds and compositions are useful in treating diabetes, obesity, and metabolic syndrome.
    Type: Application
    Filed: March 4, 2005
    Publication date: November 15, 2007
    Applicant: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, Radhakrishnan Rathnachalam, Rohn Millican, Sheng-Hung Tschang
  • Fusion Proteins
    Publication number: 20070253966
    Abstract: The invention provides active therapeutic peptides fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, reduced half antibody formation, and reduced effector activity, while not being immnunogenic. The fusion proteins are useful in treating human diseases as well as a variety of other conditions or disorders.
    Type: Application
    Filed: June 10, 2004
    Publication date: November 1, 2007
    Applicant: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, Rohn Millican Jr, Yu Tian, Sheng-Hung Tschang, Andrew Vick
  • Fgf-21 Fusion Proteins
    Publication number: 20070237768
    Abstract: The invention provides specific FGF-21 compounds fused to specific IgG4-Fc or HSA derivatives resulting in fusion proteins that are biologically active with an extended elimination half-life and a slower clearance. These FGF-21 compound fusion proteins and compositions are useful in treating type 2 diabetes, obesity, and metabolic syndrome.
    Type: Application
    Filed: May 2, 2005
    Publication date: October 11, 2007
    Applicant: ELI LILLY AND COMPANY
    Inventors: Wolfgang Glaesner, Rohn Millican, Yu Tian, Sheng-Hung Tschang
  • Erythropoietic compounds
    Publication number: 20070100133
    Abstract: The present invention addresses the need for better pharmaceutical agents for teating anemias by providing polymer derivatized non-glycosylated erythropoietic compounds which show stability and bioactivity in vivo. The invention further provides methods for preparing these derivatived proteins which involves the use of a linkerless aldehyde modification process.
    Type: Application
    Filed: September 14, 2006
    Publication date: May 3, 2007
    Inventors: John Beals, Wolfgang Glaesner, Radmila Micanovic, Rohn Millican, Derrick Witcher
  • Glp-1 analog fusion proteins
    Publication number: 20070036806
    Abstract: The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
    Type: Application
    Filed: June 10, 2004
    Publication date: February 15, 2007
    Applicant: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, Rohn Millican, Andrew Vick
  • Glucagon-like peptide-1 analogs
    Publication number: 20060263849
    Abstract: Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.
    Type: Application
    Filed: May 18, 2006
    Publication date: November 23, 2006
    Inventors: Wolfgang Glaesner, Rohn Millican
  • Glucagon-like peptide-1 analogs
    Publication number: 20060252693
    Abstract: Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 7, 8, 12, 16, 18, 19, 20, 22, 25, 27, 30, 33, and 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.
    Type: Application
    Filed: July 6, 2006
    Publication date: November 9, 2006
    Inventors: Wolfgang Glaesner, Rohn Millican, Lianshan Zhang
  • Extended glucagon-like peptide-1 analogs
    Publication number: 20060014241
    Abstract: The invention encompasses GLP-1 peptides with modifications at various positions coupled with an extended C-terminus that provides increased stability.
    Type: Application
    Filed: January 3, 2003
    Publication date: January 19, 2006
    Inventors: Wolfgang Glaesner, Wayne Kohn, Rohn Millican, Lianshan Zhang